EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Beneficial effects of chronic mexiletine treatment in a human model of SCN5A overlap syndrome

Giovanna Nasilli iD, Loukia Yiangou iD, Chiara Palandri iD, Elisabetta Cerbai iD, Richard P Davis iD, Arie O Verkerk iD, Simona Casini iD, Carol Ann Remme iD

Europace · 2023

DOI: 10.1093/europace/euad154 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Europace, 2023. Verfasst von Giovanna Nasilli und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Cardiology, Amsterdam University Medical Center, University of Amsterdam, Heart Centre, Meibergdreef 9, 1105 AZ, Amsterdam…. Hauptthemen laut MEDLINE: Long QT Syndrome, Brugada Syndrome. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Netherlands CardioVascular Research Initiative, Fondation Leducq, ZonMw Priority Medicines.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

SCN5A mutations are associated with various cardiac phenotypes, including long QT syndrome type 3 (LQT3), Brugada syndrome (BrS), and cardiac conduction disease (CCD). Certain mutations, such as SCN5A-1795insD, lead to an overlap syndrome, with patients exhibiting both features of BrS/CCD [decreased sodium current (INa)] and LQT3 (increased late INa). The sodium channel blocker mexiletine may acutely decrease LQT3-associated late INa and chronically increase peak INa associated with SCN5A loss-of-function mutations. However, most studies have so far employed heterologous expression systems and high mexiletine concentrations. We here investigated the effects of a therapeutic dose of mexiletine on the mixed phenotype associated with the SCN5A-1795insD mutation in HEK293A cells and human-induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs). Methods and results To assess only the chronic effects on trafficking, HEK293A cells transfected with wild-type (WT) SCN5A or SCN5A-1795insD were incubated for 48 h with 10 µm mexiletine followed by wash-out, which resulted in an increased peak INa for both SCN5A-WT and SCN5A-1795insD and an increased late INa for SCN5A-1795insD. Acute re-exposure of HEK293A cells to 10 µm mexiletine did not impact on peak INa but significantly decreased SCN5A-1795insD late INa. Chronic incubation of SCN5A-1795insD hiPSC-CMs with mexiletine followed by wash-out increased peak INa, action potential (AP) upstroke velocity, and AP duration. Acute re-exposure did not impact on peak INa or AP upstroke velocity, but significantly decreased AP duration.

Conclusion

These findings demonstrate for the first time the therapeutic benefit of mexiletine in a human cardiomyocyte model of SCN5A overlap syndrome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Long QT SyndromeBrugada SyndromeHumansMexiletineCardiac Conduction System DiseaseNAV1.5 Voltage-Gated Sodium ChannelAction PotentialsMyocytes, Cardiac

Stichwörter der Autor:innen

SCN5ACardiac electrophysiologyIon channelsSudden cardiac deathTherapy

Substanzen

MexiletineSCN5A protein, humanNAV1.5 Voltage-Gated Sodium Channel

Autor:innen und Institutionen

  • Department of Experimental Cardiology, Amsterdam University Medical Center, University of Amsterdam, Heart Centre, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
  • Amsterdam Cardiovascular Sciences, Heart Failure & Arrhythmias, Amsterdam, The Netherlands.
  • Department of Anatomy and Embryology, Leiden University Medical Center, Albinusdreef 2, 2300 RC, Leiden, The Netherlands.
  • Department NeuroFarBa, University of Florence, Viale Gaetano Pieraccini 6, 50139, Florence, Italy.
  • The Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), Albinusdreef 2, 2300 RC, Leiden, The Netherlands.
  • Department of Medical Biology, Amsterdam University Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.

ORCID-Profile: Giovanna Nasilli, Loukia Yiangou, Chiara Palandri, Elisabetta Cerbai, Richard P Davis, Arie O Verkerk, Simona Casini, Carol Ann Remme

Förderung

  • Netherlands CardioVascular Research Initiative
  • Fondation Leducq
  • ZonMw Priority Medicines
  • ZonMw PSIDER
  • DECIPHER
  • Novo Nordisk Foundation

Zitieren

APA

Nasilli, G., Yiangou, L., Palandri, C., Cerbai, E., Davis, R. P., Verkerk, A. O., Casini, S., & Remme, C. A. (2023). Beneficial effects of chronic mexiletine treatment in a human model of SCN5A overlap syndrome. Europace. https://doi.org/10.1093/europace/euad154

Vancouver

Nasilli G, Yiangou L, Palandri C, Cerbai E, Davis RP, Verkerk AO, et al. Beneficial effects of chronic mexiletine treatment in a human model of SCN5A overlap syndrome. Europace. 2023. doi:10.1093/europace/euad154

BibTeX
@article{Nasilli2023,
  author = {Nasilli, Giovanna and Yiangou, Loukia and Palandri, Chiara and Cerbai, Elisabetta and Davis, Richard P and Verkerk, Arie O and Casini, Simona and Remme, Carol Ann},
  title = {Beneficial effects of chronic mexiletine treatment in a human model of SCN5A overlap syndrome},
  journal = {Europace},
  year = {2023},
  doi = {10.1093/europace/euad154}
}
Kostenlos starten →